The primary objective of the CONVINCE study is to compare high-dose haemodiafiltration with high-flux haemodialysis treatment in terms of all-cause mortality.
The primary endpoint is defined as difference in rate for all-cause mortality.
- Compare high-dose high-dose haemodiafiltration with high-flux haemodialysis treatment in terms of cause specific morbidity and mortality.
- Assess patient reported outcome measures and patient reported experience measures to capture and patient perspectives and compare between high-dose haemodiafiltration with high-flux haemodialysis treatment.
3. Assess cost effectiveness of high-dose haemodiafiltration compared to high-flux haemodialysis.
The secondary endpoints are:
- Cause specific mortality (at least cardiovascular and non-cardiovascular death; others with high frequency may be added);
- Non-fatal and fatal cardiovascular events;
- Hospitalisation for infection-related conditions;
- All cause hospitalisations;
- PREMS and PROMS;
6. Cost effectiveness.